Advanced Filters
noise

Anemia; Non-Small-Cell Lung Cancer Clinical Trials

A listing of Anemia; Non-Small-Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 404 clinical trials
M Mohamed Hassanin

Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients

This study will be conducted to investigate the following: The impact of implementing GVS in MS rehabilitation on cortical excitability. The influence of GVS on upper limb function in patients diagnosed with MS. Patients will be randomly assigned to a control group (Conventional Physical Therapy program = CPT) and a …

20 - 45 years of age All Phase 1
A Andreas Wallin, Ph.D

Motor-cognitive Performance in People With Multiple Sclerosis

Having a neurological disease such as multiple sclerosis (MS) leads to difficulties in balance and gait with or without concurrent performance of cognitive tasks, hindering activity performance and influencing the possibilities for an independent lifestyle. The investigators have adapted a previously developed balance training program to a highly challenging program …

18 - 65 years of age All Phase N/A
N Nihan Çakır Biçer, PhD.

Intermittent Fasting and Mediterranean Diet in Patient With Multiple Sclerosis

When the literature was reviewed, there is no study in which the effects of intermittent fasting and Mediterranean diet on quality of life, sleep, circadian rhythm and appetite hormones leptin and ghrelin levels in MS patients were evaluated and the two diet types were comparatively examined in terms of all …

18 - 65 years of age Female Phase N/A
G Giampaolo Brichetto, MD, PhD

Feasibility of a Vocational Rehabilitation Intervention for Job Retention in Workers With MS-RiaLSM Intervention Project

Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system with both inflammatory and degenerative characteristics that affects approximately 136,000 people in Italy. The highest incidence of disease onset occurs between the ages of 20 and 40, which corresponds to the most productive period of a person's …

18 years of age All Phase N/A

Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis

The incidence of insomnia is estimated to be as high as 90% in individuals with MS due to insomnia being underdiagnosed. Sleep disturbances in people with MS have been associated with reduced cognitive performance, physical function, psychological well-being, quality of life, and occupational function, as well as increased prevalence of …

18 - 65 years of age All Phase 2
A Amir Tabatabaei Dr Tabatabaei, PhD

Dry Needling in Multiple Sclerosis

The investigators are doing this study to see if a treatment called dry needling improves muscle spasticity (muscle tightness) in people who have Multiple Sclerosis. Dry needling involves using tiny needles, like those in acupuncture, to target some muscles, like calf muscles. It differs from traditional acupuncture as it focuses …

18 - 64 years of age All Phase N/A
E Eryen Nelson, MPH

Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection

The objective of this RCT is to assess the efficacy of one-on-one telehealth CBT-I (tCBT-I) compared to web-based CBT-I (wCBT-I) and treatment as usual (TAU) to improve sleep outcomes (Aim 1), fatigue and quality of life (Aim 2), and promote neuroprotection (Exploratory Aim 3), and to explore the characteristics of …

18 - 65 years of age All Phase 2
G Guillaume MATHEY, MD

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

The goal of this randomized clinical trial is to compare relapse remitting multiple sclerosis (RRMS) patients treated by ocrelizumab or by rituximab followed for 2 years. The main question it aims to answer is : • to demonstrate the non-inferiority of rituximab versus ocrelizumab in active relapsing MS patients on …

18 - 55 years of age All Phase 3
U Uk Sok Shin

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of progressive multiple sclerosis. Half of the patients will receive NAC, while the other half will receive a placebo.

40 - 70 years of age All Phase 2
B Beata Błażejewska-Hyżorek, MD, PhD

Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

The purpose of the study is to evaluate the efficacy and safety of subcutaneously administered cladribine versus placebo to stop inflammation and treat disease progression of non-active secondary progressive multiple sclerosis. Multiple sclerosis is an inflammatory disease of the central nervous system. In most patients, it starts with a relapsing …

30 - 65 years of age All Phase 2/3

Simplify language using AI